Kirin (KNBWY)
(Delayed Data from OTC)
$14.57 USD
-0.08 (-0.51%)
Updated Apr 26, 2024 03:46 PM ET
5-Strong Sell of 5 5
D Value B Growth D Momentum C VGM
Price, Consensus and EPS Surprise
KNBWY 14.57 -0.08(-0.51%)
Will KNBWY be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for KNBWY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for KNBWY
Kirin Holdings Co. (KNBWY) Upgraded to Strong Buy: Here's Why
Take the Zacks Approach to Beat the Market: NVIDIA, Novo Nordisk, Magenta in Focus
KNBWY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Investors Undervaluing Kirin (KNBWY) Right Now?
KNBWY vs. NAPA: Which Stock Is the Better Value Option?
Should Value Investors Buy Kirin (KNBWY) Stock?
Other News for KNBWY
Introducing Bobelo's Postbiotic Immunity with IMMUSE™ for the Whole Family
OLLY Launches New Cognitive Health Supplements With 'Focus Buddies Brainy L'OLLY Pops' Including Cognizin® Citicoline
ENCORE Introduces Innovative Beverage Mixes Featuring Science-Backed Cognizin® and IMMUSE™ for Cognitive and Beauty Support
Warning: KNBWY is at high risk of cutting its dividend
First Interim Analysis of PROSPER Study Details Patient-Reported Symptom Burden of Mycosis Fungoides and Sézary Syndrome